Results 301 to 310 of about 21,171,014 (388)

Effectiveness of Octocog Alfa (BAY 81-8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset, Including Under-Represented Subgroups. [PDF]

Eur J Haematol
Chandler M, Moulton T, Charafi L, Charlet J, Recht M.   +4 more
europepmc   +1 more source

Treatment and Disease Burden in a Cohort of People With Haemophilia Without Inhibitors in the United States. [PDF]

Haemophilia
Wheeler AP, Cibelli E, Hanson G, Percier C, Porstmann T, Shridhar N, Shapiro A.   +6 more
europepmc   +1 more source

Health NGOs: a second generation of policy advocates? [PDF]

, 2008
Duckett, J.
core  

Gender, genes and genetics: from Darwin to the human genome [PDF]

, 2000
Segal, Lynne
core  

Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. [PDF]

Haemophilia
Koivusalo M, Szanto T, Kovalainen T, Vesikansa A, Laine O, Partanen A, Siitonen T, Vesanen M, Mehtälä J, Sarnesto N, Haapkylä J, Lehtinen AE, Lassila R.   +12 more
europepmc   +1 more source

The UK Infected Blood Inquiry: A Personal Reflection. [PDF]

Haemophilia
Foster PR.
europepmc   +1 more source

IMPROVED MUTATION DETECTION FOR HAEMOPHILIA A IN SOUTH AFRICA

, 2009
Claire L. Mitchell
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays

Haemophilia, 2021
Emicizumab is a recombinant, humanized bispecific monoclonal antibody that mimics the function of factor VIII (FVIII) which results in a significant reduction in the annualized bleeding rate in patients with haemophilia A (HA), however, the degree with ...
Hande Kızılocak, E. Marquez-Casas, J. Malvar, R. Carmona, G. Young   +4 more
semanticscholar   +1 more source

Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature

Haemophilia, 2021
Since the approval of emicizumab, a bispecific, factor VIII‐mimetic antibody, for use in persons with congenital haemophilia A in 2018, there have been increasing case reports and case series of off‐label use of emicizumab in other bleeding disorders ...
V. Thomas, Mouhamed Yazan Abou-Ismail, Ming Y. Lim   +2 more
semanticscholar   +1 more source